Personal reflections on efforts to reduce ischemic myocardial damage

Cardiovascular Research

Volumn 56, Issue 3, 2002, Pages 332-338

  Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CARDIOLOGY; CAROTID SINUS NERVE; CONGESTIVE HEART FAILURE; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DEFIBRILLATION; EDITORIAL; HEALTH CARE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEMODYNAMICS; HIBERNATION; ISCHEMIA; MEDICAL RESEARCH; MEDICAL STUDENT; NERVE STIMULATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUTOBIOGRAPHY; CARDIOLOGY; HISTORY, 20TH CENTURY; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 0036890120     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00643-0     Document Type: Editorial

References (61)

1. Krehl L. Die Ekrankungen des Herzmuskels und die Nervosen Herzkrankheiten. 1901;Alfred Holder, Vienna.
2. Obrastzov W.P., Strashesko N.D. Zur Kenntnis der Thrombose der Koronararterien des Herzens. Z Klin Med. 71:1910;116-132.
3. Herrick J.B. Certain clinical features of sudden obstruction of the coronary arteries. J Am Med Assoc. 59:1912;2015-2020.
4. Braunwald E. Evolution of the management of acute myocardial infarction. Lancet. 352:1998;1771-1774.
5. Sarnoff S.J., Braunwald E., Welch G.H. Jr., et al. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol. 192:1958;148-156.
6. Braunwald E., Sarnoff S.J., Case R.B., et al. Hemodynamic determinants of coronary flow: Effect of changes in aortic pressure and cardiac output on the relationship between myocardial oxygen consumption and coronary flow. Am J Physiol. 192:1958;157-163.
7. Sonnenblick E.H., Ross J. Jr., Covell J.W., Kaiser G.A., Braunwald E. Velocity of contraction as a determinant of myocardial oxygen consumption. Am J Physiol. 209:1965;919-927.
8. Covell J.W., Ross J. Jr., Taylor R., Sonnenblick E.H., Braunwald E. Effects of increasing frequency of contraction on the force velocity relation of left ventricle. Cardiovasc Res. 1:1967;2-8.
9. Ross J. Jr., Frahm C.J., Braunwald E. Influence of the carotid baroreceptors and of vasoactive drugs on systemic vascular volume and venous distensibility. Circ Res. 9:1961;75-82.
10. Braunwald E., Epstein S.E., Glick G., Wechsler A., Braunwald N.S. Relief of angina pectoris by electrical stimulation of the carotid sinus. New Engl J Med. 277:1967;1278-1283.
11. Epstein S.E., Beiser G.D., Goldstein R.E., et al. Circulatory effects of electrical stimulation of the carotid sinus nerves in man. Circulation. 40:1969;269-276.
12. Tennant R., Wiggers C.J. The effect of coronary occlusion on myocardial contraction. Am J Physiol. 112:1935;351-361.
13. Blumgart H.L., Gilligan D.R., Schlesinger M.J. Experimental studies on the effect of temporary occlusion of coronary arteries. Am. Heart J. 22:1941;374-389.
14. Braunwald E. The pathogenesis and treatment of shock in myocardial infarction. Johns Hopkins Med J. 121:1967;421-429.
15. Braunwald E., Covell J.W., Maroko P.R., Ross J. Jr. Effect of drugs and of counterpulsation on myocardial oxygen consumption. Circulation. 40:(Suppl IV):1969;220-228.
16. Maroko P., Kjekshus J.K., Sobel B.E., et al. Factors influencing infarct size following experimental coronary artery occlusion. Circulation. 43:1971;67-82.
17. Maroko P.R., Braunwald E. Modification of myocardial infarct size after coronary occlusion. Ann Intern Med. 79:1973;720-733.
18. Maroko P.R., Libby P., Ginks W.R., et al. Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest. 51:1972;2710-2716.
19. Ginks W.R., Sybers H.D., Maroko P.R., et al. Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest. 51:1972;2717-2723.
20. Maroko P.R., Davidson D.M., Libby P., Hagan A.D., Braunwald E. Effects of hyaluronidase administration on myocardial ischemic injury in acute infarction. Ann Intern Med. 82:1975;516-520.
21. Reimer K.A., Lowe J.E., Rasmussen M.M., Jennings R.B. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation. 56:1977;786-794.
22. Tillett W.S., Garner R.L. The fibrinolytic activity of hemolytic streptococci. J Exp Med. 58:1933;485-502.
23. Chazov E.I., Matveeva L.S., Mazaev A.V., et al. Intracoronary administration of thrombolysin in acute myocardial infarction. Terapeuticheskii Arkhiv. 48:1976;8-19.
24. Rentrop P., DeVivie E.R., Karsch K.R., Kreuzer H. Acute coronary occlusion with impending infarction as an angiographic complication relieved by a guidewire recanalization. Clin Cardiol. 1:1978;101-106.
25. Markis J.E., Malagold M., Parker J.A., et al. Myocardial salvage after intracoronary thrombolysis with streptokinase in acute myocardial infarction: Assessment of intracoronary thallium-201. New Engl J Med. 305:1981;777-782.
26. The TIMI Study Group . The thrombolysis in myocardial infarction (TIMI) trial. Phase I. Findings. New Engl. J. Med. 312:1985;932-936.
27. Williams D.O., Borer J., Braunwald E., et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. A report from the NHLBI thrombolysis in myocardial infarction trial. Circulation. 73:1986;338-346.
28. Dalen J.E., Gore J.M., Braunwald E., et al. Six and twelve-month follow-up of the Phase I thrombolysis in myocardial infarction (TIMI) trial. Am J Cardiol. 62:1988;179-185.
29. The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med. 329:1993;673.
30. Kim C.B., Braunwald E. Potential benefits of late reperfusion of infarcted myocardium: The open artery hypothesis. Circulation. 88:1993;2426-2436.
31. Braunwald E. The open-artery theory is alive and well - again. New Engl J Med. 329:1993;1650-1652.
32. Cannon C.P., Antman E.M., Walls R., Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis. 1:1994;27-33.
33. Roberts R., Rogers W.J., Mueller H.S., et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation. 83:1991;422-437.
34. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 93:1996;879-888.
35. Gibson C.M., Cannon C.P., Murphy S.A., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 101:2000;125-130.
36. deLemos J.A., Braunwald E. ST-segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol. 38:2001;1283-1294.
37. Cannon C.P., Gibson C.M., McCabe C.H., et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation. 98:1998;205-214.
38. Morrow D.A., Antman E.M., Sayah A., et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation MI: results of the early retevase (ER)-TIMI 19 trial. J Am Coll Cardiol. 40:2002;71-77.
39. Antman E.M., Giugliano R.P., Gibson C.M., et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI 14) trial. Circulation. 99:1999;2720.
40. The TIMI IIIB Investigators . Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial. Circulation. 89:1994;1545-1556.
41. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the TIMI IIB trial. Circulation. 100:1999;1593-1601.
42. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. New Eng J Med. 344:2001;1879-1887.
43. Antman E.M., Cohen M., Bernink P.J.L.M., et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. J Am Med Assoc. 284:2000;835-842.
44. Antman E.M., Tanasijevic M.J., Thompson B., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. New Eng J Med. 335:1996;1342-1349.
45. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes. A TIMI 11A substudy. J Am Coll Cardiol. 31:1998;1460-1465.
46. deLemos J.A., Morrow D.A., Bentey J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. New Engl J Med. 345:2001;1014-1021.
47. Sabatine M.S., Morrow D.A., deLemos J., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 105:2002;1760-1763.
48. Heyndrickx G.R., Baig H., Nellers P., et al. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am. J. Physiol. 234:1978;H653.
49. Braunwald E., Kloner R.A. The stunned myocardium: Prolonged postischemic ventricular dysfunction. Circulation. 66:1982;1146-1149.
50. Cooper H.A., Braunwald E. Clinical importance of stunned and hibernating myocardium. Coron Arter Dis. 12:2001;387-392.
51. Rahimtoola S.H. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 68:(Suppl. II):1983;8-15.
52. Braunwald E., Rutherford J.D. Reversible ischemic left ventricular dysfunction: evidence for the hibernating myocardium [editorial]. J Am. Coll. Cardiol. 8:1986;1467-1470.
53. Pfeffer J.M., Pfeffer M.A., Fletcher P.J., Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol. 260:1991;H1406-H1414.
54. Pfeffer M.A., Braunwald E. Ventricular remodeling following myocardial infarction: experimental observations and clinical implications. Circulation. 81:1990;1161-1172.
55. Pfeffer J.M., Pfeffer M.A., Braunwald E. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation. 75:(Suppl 1):1987;I149-I155.
56. Pfeffer M.A., Lamas G.A., Vaughan D.E., Parisi A.F., Braunwald E. Effects of captopril on progressive ventricular dilation after anterior myocardial infarction. New Engl J Med. 319:1988;80-86.
57. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement (SAVE) trial. New Engl J Med. 327:1992;669-677.
58. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: results of the cholesterol and recurrent events (CARE) trial. New Engl J Med. 335:1996;1342-1349.
59. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:1999;230-235.
60. Blazing M.A., deLemos J.A., Dyke C.K., et al. The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of an early aggressive simvastatin therapy. Am Heart J. 142:2001;211-217.
61. Cannon C.P., McCabe C.H., Belder R., Breen J., Braunwald E. Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 89:2002;860-861.